We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Natural Method for Clearing Cellular Debris Inspires Lupus Treatment

By LabMedica International staff writers
Posted on 06 Mar 2012
Cells that die naturally generate a large amount of internal debris that can trigger the immune system to attack the body, leading to diseases such as lupus. Now, researchers report that an enzyme known to help keep a woman’s immune system from attacking a fetus also helps block development of these autoimmune diseases that target healthy tissues.

The study’s findings lead to toward new treatment approaches for autoimmune diseases, which are increasing in light of a germ-conscious society that regularly destroys many of the previously pervasive microbes that made the immune system more tolerant. “The basic premise of lupus is you have lost normal tolerance to yourself, your own proteins, and DNA,” said Dr. Tracy L. McGaha, Georgia Health Sciences University (GHSU; Augusta, USA) immunologist and corresponding author of the study published ahead of print February 21, 2012, in the journal Proceedings of the [US] National Academy of Sciences.

The investigators discovered that IDO, or indoleomine 2,3-dioxegenase, helps promote tolerance to debris generated by natural cell death and that when IDO is removed from the mixture, the debris triggers an immune response that can induce autoimmune disease. In mice genetically engineered to develop lupus, blocking IDO resulted in earlier, more aggressive disease. “This connects IDO and macrophages. It’s a newly described role for IDO in regulation of tolerance toward self,” Dr. McGaha remarked. Accordingly, increasing IDO production or its downstream effects might be a way to regain lost tolerance, he said.

The researchers assessed activity in the spleen; a hard-working immune organ that constantly filters blood. In a flawlessly organized defense, the entrance to the spleen is surrounded by immune cells that search the blood for viruses, bacteria, even fat and cholesterol floating by.

A neighboring subset of macrophages, which are basically scavengers, then capture and consume the undesirables, according to Dr. McGaha said. Fascinatingly, a lot of what macrophages consume is dead immune cells.

Macrophages also appear to help keep the peace by preventing the immune system from joining the fray. Dr. McGaha earlier found that if he destroyed macrophages, then fed the spleen dead cells, there was inflammation instead of calm. “That tells us there is something inherent in this subset of macrophages that is important for the suppressive process,” Dr. McGaha said referencing the study published in 2011 in the journal Blood.

The new study revealed that IDO is part of that “something.” Efficient elimination of cell debris while keeping nearby immune cells quiet is important because some debris is known to grab the attention of the immune system, According to Dr. McGaha. He noted that it is normal--and healthy--for damaged cells to become targets. “We are really interested in this process of normal cell debris removal because in lupus, it's thought to be one of the main drivers of inflammation,” he said.

The immune system has points of expansion and regulation where it decides whether or not to act. Knowing key points, such as IDO’s regulatory role, provides treatment targets that can interrupt a destructive cascade of immune activity, Dr. McGaha noted. Earlier research has shown evidence of self-attack is present many years before disease symptoms appear, he said.

Environmental hazards, such as a nasty sunburn, can be the first trigger of the abnormal immune response in diseases such as lupus. In healthy individuals, the immune system rises to the occasion of an infection then goes back to baseline. In autoimmune disease, patients tend not to return to normal levels.

GHSU’s Drs. Andrew Mellor and David Munn reported in 1998 in the journal Science that the fetus expresses IDO to help avoid rejection by the mother’s immune system. Following studies have shown tumors also use it and that it could help transplanted organs escape rejection. They suggested that Dr. McGaha evaluate IDO as a regulatory process used by macrophages.

Related Links:
Georgia Health Sciences University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
Thyroid Test
Anti-Thyroid EIA Test

Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more